Search results
Combination Targeted Treatment Produces Lasting Remissions in People with Resistant Aggressive B-...
Sierra Sun Times· 4 days agoCombination therapy developed by NIH researchers demonstrates the power of precision medicine. June...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 5 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
...Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to...
Morningstar· 5 days agoALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who
Living Drugs that Fight Cancer | Newswise
Newswise· 1 day agoAlthough the process collects patients’ own white blood cells, they must still undergo a mild chemotherapy to weaken their immune systems — known as...
NIH Phase Ib/II DLBCL drug combo trial reports 34% complete response
Clinical Trials Arena via Yahoo Finance· 5 days agoA five drug combination drug therapy trial has shown substantial tumour shrinking in more than half...
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach...
Morningstar· 5 days agoPALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western
Xencor (XNCR) – Research Analysts’ Weekly Ratings Updates
ETF DAILY NEWS· 5 hours ago6/14/2024 – Xencor had its price target lowered by analysts at Raymond James from $58.00 to $40.00. 6/14/2024 – Xencor had its price target lowered by analysts at BMO Capital Markets from $34.00 ...
Music therapy helps two-time cancer survivor throu | Newswise
Newswise· 4 days agoLEXINGTON, Ky. (June 21, 2024) – In 2018, Bobbi Jo Allen was exercising when she found a lump in her...
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
MedPage Today· 6 days agoHigh-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line
Glofitamab Regimen Improves Survival in DLBCL
MedPage Today· 5 days agoGranted accelerated approval last year, bispecific antibody passes its confirmatory test